Devyser wins tender in Italy worth approximately SEK 5.7 million – doubling test volumes compared with previous agreement
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
This paper by Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital, Sweden, highlights the importance of chimerism as a diagnostic tool for clinicians treating transplanted patients. Furthermore, the evolution of novel diagnostic tools for early detection of mixed chimerism is discussed. The recent development of NGS technology offers the possibility to analyze mixed chimerism with both sensitivity, as well as accurate and precise determination.
This paper by Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital, Sweden, highlights the importance of chimerism as a diagnostic tool for clinicians treating transplanted patients. Furthermore, the evolution of novel diagnostic tools for early detection of mixed chimerism is discussed. The recent development of NGS technology offers the possibility to analyze mixed chimerism with both sensitivity, as well as accurate and precise determination.
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
Read More
Devyser announced that One Lambda™ Devyser Accept cfDNA, its test for monitoring kidney transplant...
Read More
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial...
Read More
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More